Number of shares and votes in Oncopeptides
STOCKHOLM, July 29, 2022 /PRNewswire/ — Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s share issue as announced on July 14, 2022. As a result of the share issue, the number of outstanding shares and votes has increased by 15,061,443 from 75,307,217 to 90,368,660. The share capital has increased by approximately SEK 1,673,494 from SEK 8,367,469 to SEK 10,040,963.
For further information, please contact:
Annika Muskantor, CFO, Oncopeptides AB (publ)
Mobil: +46 70 823 86 91
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ)
Mobil: + 46 70 262 96 28
The information in the press release is information that Oncopeptides is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons above, on July 29, 2022, at 08.00 (CEST).
Oncopeptides is a biotech company focused on research and development of pharmaceuticals for difficult-to-treat haematological diseases. The company uses its proprietary PDC platform to develop peptide-drug conjugated compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from the PDC platform, Pepaxto®
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release – Number of shares and votes in Oncopeptides
View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-oncopeptides-301595943.html
SOURCE Oncopeptides AB
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.